PET theranostics is transforming precision oncology, yet treatment response varies substantially; many patients receiving 177Lu-PSMA radioligand therapy (RLT) for metastatic castration-resistant prostate cancer (mCRPC) fail to respond, demanding reliable pre-therapy prediction. While LLM-based agents have shown remarkable potential in complex medical diagnosis, their application to PET theranostic outcome prediction remains unexplored, which faces three key challenges: (1) data and knowledge scarcity: RLT was only FDA-approved in 2022, yielding few training cases and insufficient domain knowledge in general LLMs; (2) heterogeneous information integration: robust prediction hinges on structured knowledge extraction from PET/CT, laboratory tests, and free-text clinical documentation; (3) evidence-grounded reasoning: clinical decisions must be anchored in trial evidence rather than LLM hallucinations. In this paper, we present TheraAgent, to our knowledge, the first agentic framework for PET theranostics, with three core innovations: (1) Multi-Expert Feature Extraction with Confidence-Weighted Consensus, where three specialized experts process heterogeneous inputs with uncertainty qua
Quantitative molecular imaging is central to treatment response assessment in oncology, yet clinical practice remains largely dominated by patient-level or limited target-lesion criteria that ignore inter-lesion heterogeneity. This limitation is particularly important in prostate cancer, where PSMA PET/CT can reveal extensive skeletal and nodal metastatic disease that often evolves heterogeneously under therapy. Accurate and scalable lesion segmentation and tracking across serial PSMA PET/CT and post-therapy SPECT/CT scans is therefore essential for implementing emerging PSMA-specific response frameworks, such as RECIP 1.0, and for enabling lesion-level dosimetry in 177Lu-PSMA radiopharmaceutical therapies (RPTs). This article examines clinical motivations, technical foundations, and future pathways for automated lesion tracking in prostate cancer imaging. We focus on the unique requirements introduced by PSMA PET/CT compared with FDG PET/CT and highlight the critical role of quantitative SPECT/CT in linking imaging-derived disease characterization with delivered therapeutic dose. Recent advances in AI-based segmentation and automated lesion matching now make scalable longitudinal
Long-axial field-of-view (LAFOV) PET/CT has the potential to redefine the role of molecular imaging in theranostics by making multiparametric whole-body (MPWB) imaging and predictive dosimetry more clinically feasible. Compared to conventional PET systems, LAFOV scanners provide dramatic gains in sensitivity and coverage, allowing dynamic acquisitions, delayed imaging, and dual-tracer protocols within clinically feasible workflows. These advances supply the quantitative data required for physiologically based pharmacokinetic (PBPK) modeling and the creation of theranostic digital twins, supporting true personalization of radiopharmaceutical therapy.
Cancer remains a leading cause of death worldwide, necessitating personalized treatment approaches to improve outcomes. Theranostics, combining molecular-level imaging with targeted therapy, offers potential for precision oncology but requires optimized, patient-specific care plans. This paper investigates state-of-the-art data-driven decision support applications with a reinforcement learning focus in precision oncology. We review current applications, training environments, state-space representation, performance evaluation criteria, and measurement of risk and reward, highlighting key challenges. We propose a framework integrating data-driven modeling with reinforcement learning-based decision support to optimize radiopharmaceutical therapy dosing, addressing identified challenges and setting directions for future research. The framework leverages Neural Ordinary Differential Equations and Physics-Informed Neural Networks to enhance Physiologically Based Pharmacokinetic models while applying reinforcement learning algorithms to iteratively refine treatment policies based on patient-specific data.
Traditional sources of quantum-entangled photons, such as spontaneous parametric down-conversion, suffer from low flux, limiting clinical applications. We investigated whether clinical megavoltage (MV) radiotherapy beams can serve as dual-purpose sources, delivering therapeutic dose while simultaneously generating high-flux entangled photon pairs for quantum ghost imaging, quantum theranostics (QTX), and related applications. Using GEANT4 Monte Carlo simulations, we modeled water-equivalent phantoms containing 2 cm spherical tumors loaded with gold nanoparticles (AuNPs, 10 mg/mL). Clinical spectra at 6, 10, and 15 MV were simulated. Key metrics included 511 keV photon-pair yield, positronium lifetimes (time-resolved), Doppler and energy broadening (energy-resolved), signal-to-noise ratios (SNR), and entanglement retention at depths from 5 to 15 cm. Pair yields scaled with beam energy and AuNP concentration, reaching about 10^8 pairs per Gy per cm^3 in AuNP-loaded tumors. Positronium lifetime shifts (about 100 ps) reflected tumor oxygenation and reactive oxygen species, offering potential functional biomarkers. Doppler (1-3 keV) and AuNP-induced line broadening (0.5-1 keV) produced
The theranostic paradigm enables personalization of treatment by selecting patients with a diagnostic radiopharmaceutical and monitoring therapy using a matched therapeutic isotope. This strategy relies on accurate image reconstruction of both pretherapy and post-therapy images for patient selection and monitoring treatment. However, traditional reconstruction methods are hindered by challenges such as crosstalk in multi-isotope imaging and extremely low-count measurements data when imaging of alpha-emitting isotopes. Additionally, to fully realize the benefits of new imaging systems being developed for theranostic applications, advanced reconstruction techniques are needed. This review highlights recent progress and discusses critical challenges and unmet needs in theranostic image reconstruction.
Theranostics, the combination of diagnosis and therapy, has long held promise as a means to achieving personalised precision cancer treatments. However, despite its potential, theranostics has yet to realise significant clinical translation, largely due the complexity and overriding toxicity concerns of existing theranostic nanoparticle strategies. Here, we present an alternative nanoparticle-free theranostic approach based on simultaneous Raman spectroscopy and photodynamic therapy (PDT) in an integrated clinical platform for cancer theranostics. We detail the compatibility of Raman spectroscopy and PDT for cancer theranostics, whereby Raman spectroscopic diagnosis can be performed on PDT photosensitiser-positive cells and tissues without inadvertent photosensitiser activation/photobleaching or impaired diagnostic capacity. We further demonstrate that our theranostic platform enables in vivo tumour diagnosis, treatment, and post-treatment molecular monitoring in real-time. This system thus achieves effective theranostic performance, providing a promising new avenue towards the clinical realisation of theranostics.
We highlight emerging uses of artificial intelligence (AI) in the field of theranostics, focusing on its significant potential to enable routine and reliable personalization of radiopharmaceutical therapies (RPTs). Personalized RPTs require patient-individual dosimetry calculations accompanying therapy. Image-based dosimetry needs: 1) quantitative imaging; 2) co-registration and organ/tumor identification on serial and multimodality images; 3) determination of the time-integrated activity; and 4) absorbed dose determination. AI models that facilitate these steps are reviewed. Additionally we discuss the potential to exploit biological information from diagnostic and therapeutic molecular images to derive biomarkers for absorbed dose and outcome prediction, towards personalization of therapies. We try to motivate the nuclear medicine community to expand and align efforts into making routine and reliable personalization of RPTs a reality.
Confocal laser endomicroscopy (CLE) is an advanced optical fluorescence imaging technology that has the potential to increase intraoperative precision, extend resection, and tailor surgery for malignant invasive brain tumors because of its subcellular dimension resolution. Despite its promising diagnostic potential, interpreting the gray tone fluorescence images can be difficult for untrained users. In this review, we provide a detailed description of bioinformatical analysis methodology of CLE images that begins to assist the neurosurgeon and pathologist to rapidly connect on-the-fly intraoperative imaging, pathology, and surgical observation into a conclusionary system within the concept of theranostics. We present an overview and discuss deep learning models for automatic detection of the diagnostic CLE images and discuss various training regimes and ensemble modeling effect on the power of deep learning predictive models. Two major approaches reviewed in this paper include the models that can automatically classify CLE images into diagnostic/nondiagnostic, glioma/nonglioma, tumor/injury/normal categories and models that can localize histological features on the CLE images using
The field of infrared (IR) photonics is currently undergoing remarkable progress, moving rapidly towards practical sensing applications demanded by medical therapy and diagnostics (theranostics). The Developments can be divided into three main categories: (i) novel devices and measurement concepts including advanced updates of classical approaches that push medical sensing into the spotlight; (ii) new demonstrations of photonic integrated circuit (PIC-)based IR devices enabling highly miniaturized sensors for point-of-care application as well as medical and wellness wearables; and (iii) technologically-mature IR demonstrators that enable first medical sensing and treatment applications. This roadmap paper provides a consolidated overview of this highly dynamic and interdisciplinary research field with a focus on the major roadblocks that limit the widespread adoption of IR photonics in large-scale medical diagnostics. Special attention is given to the ambivalence between the molecular-level spectroscopic interpretation and a broader health-state assessment, highlighting the need for a common framework. Additionally, the paper discusses the critical importance of unified measurement
In this work, we investigate the thermoacoustic generation and propagation of spherical waves in a viscous fluid induced by a laser-heated spherical particle. Periodic laser excitation gives rise to two coupled mechanisms of acoustic emission. Heat transfer from the particle to the surrounding fluid produces periodic compressions and rarefactions, giving rise to the thermophone effect, while periodic thermal expansion of the solid particle modulates its radius and launches acoustic waves through a piston-like action, known as the mechanophone effect. The thermophone contribution dominates at low frequencies, whereas the mechanophone mechanism becomes more relevant at higher frequencies, with the crossover governed by the interfacial thermal resistance at the solid-fluid boundary. We investigate the effect of nanoparticle embedding fluid viscosity on acoustic wave propagation. Viscous dissipation has a significant impact on attenuation and substantially alters the acoustic penetration depth, thereby affecting the effectiveness of the signal transmission. Viscous damping plays a key role in the mechanophone effect, where hypersonic frequency waves are generated, notably by photoacous
Radiopharmaceutical therapies are expanding rapidly, but clinical evidence generation is limited by operational constraints and biological heterogeneity in radiopharmaceutical delivery and radiation risk. Virtual theranostic trials can run as companion trials, linking quantitative imaging to patient-specific models to generate evidence for personalized injections and scheduling, accelerate development, and broaden access.
Understanding the molecular-level mechanisms underpinning Alzheimer's disease (AD) by studying crucial genes associated with the disease remains a challenge. Alzheimer's, being a multifactorial disease, requires understanding the gene-gene interactions underlying it for theranostics and progress. In this article, a novel attempt has been made using a quantum regression to decode how some crucial genes in the AD Amyloid Beta Precursor Protein ($APP$), Sterol regulatory element binding transcription factor 14 ($FGF14$), Yin Yang 1 ($YY1$), and Phospholipase D Family Member 3 ($PLD3$) etc. become influenced by other prominent switching genes during disease progression, which may help in gene expression-based therapy for AD. Our proposed Quantum Regression Network (Alz-QNet) introduces a pioneering approach with insights from the state-of-the-art Quantum Gene Regulatory Networks (QGRN) to unravel the gene interactions involved in AD pathology, particularly within the Entorhinal Cortex (EC), where early pathological changes occur. Using the proposed Alz-QNet framework, we explore the interactions between key genes ($APP$, $FGF14$, $YY1$, $EGR1$, $GAS7$, $AKT3$, $SREBF2$, and $PLD3$) wit
Predictive dosimetry is central to enabling personalized radiopharmaceutical therapy (RPT), particularly in prostate specific membrane antigen (PSMA) targeted theranostics. In this work, we develop a three layer computational framework that integrates physiologically based pharmacokinetic (PBPK) modeling with machine learning (ML) to predict both physical (AUC, absorbed dose) and biological (BED, EQD2) dosimetric endpoints in tumors and major organs. In the first layer, we generated 640 virtual patients using PBPK simulations of F-18, Ga-68, and Cu-64 labeled PSMA PET tracers paired with Lu-177 PSMA therapy, producing 15360 tumor and organ time activity curves (TACs) under realistic biological variability and PET-like noise. In the second layer, TACs were transformed into quantitative kinetic features and mapped to physical and biological dose metrics. In the third layer, ML models (Random Forest, Extra Trees, Ridge, Gradient Boosting, and XGBoost) were trained to predict RPT doses from PET derived features, with performance evaluated using mean absolute percentage error (MAPE) and R2. Cu-64 PSMA-617 based PET yielded the most robust predictions, achieving tumor dose MAPE as low as
Physiologically based pharmacokinetic (PBPK) models provide a mechanistic framework for simulating radiopharmaceutical kinetics and estimating patient-specific absorbed doses (ADs). PBPK models incorporate prior knowledge of patient physiology and drug-specific properties, which can enhance the models predictive performance. PBPK models can ultimately be used to predict treatment response and thereby enable theranostic digital twins (TDTs) for personalized treatment planning in radiopharmaceutical therapies (RPTs). To achieve this potential of precision RPT, however, the reliability of the underlying modeling, including the PBPK-based dosimetry, must be established through rigorous verification, validation, and uncertainty quantification (VVUQ). This review outlines the role of VVUQ in ensuring the credibility and clinical applicability of PBPK models in radiotheranostics. Key methodologies for PBPK model VVUQ are discussed, including goodness-of-fit (GOF) assessment, prediction evaluation, and uncertainty propagation.
X-ray fluorescence computed tomography (XFCT), a form of X-ray molecular imaging, offers detailed quantitative imaging capabilities for high-Z metal nanoparticles (MNPs), which are widely studied for their applications in multifunctional theranostics. Due to its affordability and accessibility, the benchtop XFCT prototype typically employs a single-pixel detector (SPD) with single-pencil-beam (SPB) X-ray excitation. While this design (resembling the first-generation CT geometry) achieves reliable detection sensitivity, it is hindered by long imaging times. The use of simultaneous multiple-pencil-beam (MPB) excitation presents a promising solution to significantly reduce imaging times. In this study, we developed a repeatable workflow that combines Monte Carlo (MC) simulations and 3D printing to design Nbeam-MPB collimator, where Nbeam is the number of beams generated by the collimator. As an initial test, we fabricated a 2-MPB collimator and evaluated the performance of 2-MPB-based XFCT imaging on a physical phantom and small animals surgically implanted with agarose pellets containing gold chloride (H[AuCl4]). The results demonstrated a 2x acceleration in image acquisition without
KEY WORDS: Artificial Intelligence (AI), Theranostics, Dosimetry, Radiopharmaceutical Therapy (RPT), Patient-friendly dosimetry KEY POINTS - The rapid evolution of radiopharmaceutical therapy (RPT) highlights the growing need for personalized and patient-centered dosimetry. - Artificial Intelligence (AI) offers solutions to the key limitations in current dosimetry calculations. - The main advances on AI for simplified dosimetry toward patient-friendly RPT are reviewed. - Future directions on the role of AI in RPT dosimetry are discussed.
This article presents the general framework of theranostic digital twins (TDTs) in computational nuclear medicine, designed to support clinical decision-making and improve cancer patient prognosis through personalized radiopharmaceutical therapies (RPTs). It outlines potential clinical applications of TDTs and proposes a roadmap for successful implementation. Additionally, the chapter provides a conceptual overview of the current state of the art in the mathematical and computational modeling of RPTs, highlighting key challenges and the strategies being pursued to address them.
One of the current trends of laser applications in material science is using high-intensity lasers to provide fast and efficient surface or volume modifications for achieving controllable material properties, synthesis of novel materials with desired functionalities, and upscaling laser technologies with industry-demanded throughputs. Depending on the parameters, lasers can offer versatile solutions for scientific and industrial applications, starting from exploring the fundamental physics of warm dense matter and molecular chemistry at ultrashort timescales to large-scale fabrication of surfaces with anti-bacterial, tribological, hydrophobic, or hydrophilic properties. The objectives of this Chapter are to provide a review of recent advancements in several laser application fields, which involve high-intensity lasers, both ultrashort (femto- and picosecond) and short (nanosecond). After summarizing general trends in high-intensity laser processing of materials, we will first focus on the new opportunities offered by high-intensity lasers for the controlled synthesis of multielement nanoparticles for catalytic and theranostic applications. Then, the blister-based laser-induced forw
Glioblastoma (GBM) is an aggressive and fatal tumor. The infiltrative spread of GBM cells hinders the gross total resection. The residual GBM cells are significantly associated with survival and recurrence. Therefore, a theranostic method that can enhance the contrast between residual GBM and normal astrocyte (AS) cells as well as selectively eradicate GBM cells is highly desired. In this report, GBM and normal astrocyte cells are both cultured in the same microplate well to imitate a coexistence environment and treated with Raman tags functionalized by anti-EGFR. Compared to AS cells, GBM cells show 25% higher Raman emission, and their cell death rate increases by a factor of 2. These results demonstrate potential for selective eradication of the residual GBM cells guided by robust Raman signals after the primary GBM surgery.